Kura Oncology Inc KURA

US Biotechnology

$9.01 ▼ -3.22% ($-0.30)

📅 Earnings This Week

Open $9.47

Prev Close $9.31

Day Range $8.87 – $9.47

52W Range $5.45 – $12.49

Market Cap $799.86M

Beta 0.38

EPS (TTM) $-3.35

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2015-11-05
Shares Out.	88,770,000
Website	kuraoncology.com/ ↗
Phone	13026587581
Employees	260
Revenue	$18.3M
Gross Profit	$18.0M
Net Income	-$73.3M
Free Cash Flow	-$84.5M
Total Assets	$652.6M
Total Liabilities	$544.7M
Equity	$107.9M

About Kura Oncology Inc

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Kura Oncology Inc is a publicly traded company under the ticker symbol KURA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.